These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 15327428)

  • 1. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease.
    Kosch M; Koch HG; Oliveira JP; Soares C; Bianco F; Breuning F; Rasmussen AK; Schaefer RM
    Kidney Int; 2004 Sep; 66(3):1279-82. PubMed ID: 15327428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
    Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
    Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.
    Eng CM; Banikazemi M; Gordon RE; Goldman M; Phelps R; Kim L; Gass A; Winston J; Dikman S; Fallon JT; Brodie S; Stacy CB; Mehta D; Parsons R; Norton K; O'Callaghan M; Desnick RJ
    Am J Hum Genet; 2001 Mar; 68(3):711-22. PubMed ID: 11179018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease: kidney involvement and enzyme replacement therapy.
    Siamopoulos KC
    Kidney Int; 2004 Feb; 65(2):744-53. PubMed ID: 14717955
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies.
    Thurberg BL; Randolph Byers H; Granter SR; Phelps RG; Gordon RE; O'Callaghan M
    J Invest Dermatol; 2004 Apr; 122(4):900-8. PubMed ID: 15102080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
    Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
    Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
    Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
    Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients.
    Nishino T; Obata Y; Furusu A; Hirose M; Shinzato K; Hattori K; Nakamura K; Matsumoto T; Endo F; Kohno S
    Ren Fail; 2012; 34(5):566-70. PubMed ID: 22563919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
    Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
    Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
    Talbot AS; Lewis NT; Nicholls KM
    Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-galactosidase A activity levels in Turkish male hemodialysis patients.
    Kalkan Uçar S; Sozmen E; Duman S; Başçi A; Çoker M
    Ther Apher Dial; 2012 Dec; 16(6):560-5. PubMed ID: 23190516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up.
    Tsambaos D; Chroni E; Manolis A; Monastirli A; Pasmatzi E; Sakkis T; Davlouros P; Goumenos D; Katrivanou A; Georgiou S
    Acta Derm Venereol; 2004; 84(5):389-92. PubMed ID: 15370707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients.
    Kotanko P; Kramar R; Devrnja D; Paschke E; Voigtländer T; Auinger M; Pagliardini S; Spada M; Demmelbauer K; Lorenz M; Hauser AC; Kofler HJ; Lhotta K; Neyer U; Pronai W; Wallner M; Wieser C; Wiesholzer M; Zodl H; Födinger M; Sunder-Plassmann G
    J Am Soc Nephrol; 2004 May; 15(5):1323-9. PubMed ID: 15100373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
    Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
    Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefit of enzyme replacement therapy in Fabry disease.
    Breunig F; Weidemann F; Strotmann J; Knoll A; Wanner C
    Kidney Int; 2006 Apr; 69(7):1216-21. PubMed ID: 16609685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Factors which influence phosphorus removal in hemodialysis].
    Gallar P; Ortiz M; Ortega O; Rodríguez I; Seijas V; Carreño A; Oliet A; Vigil A
    Nefrologia; 2007; 27(1):46-52. PubMed ID: 17402879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
    Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
    Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Fabry disease among Turkish dialysis patients: Data from hemodialysis centers in Bursa province.
    Sayilar EI; Ayar Y; Yavuz M
    Clin Nephrol; 2016 Mar; 85(3):165-72. PubMed ID: 26833297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of Fabry disease.
    Kleinert J; Hauser AC; Lorenz M; Födinger M; Sunder-Plassmann G
    Kidney Int; 2004 Sep; 66(3):1288; author reply 1288-9. PubMed ID: 15327431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.